Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib rollover continued-access study
NL-OMON39584Phase 2Active, not recruiting
- Sponsor
- AVEO Oncology
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in gastrointestinal cancer, sponsored by AVEO Oncology. Primary endpoints: Adverse events and Tumor growth. Started Feb 2012; status: active, not recruiting.
02
Drugs
tivozanib
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NL-OMON39584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39584.